In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition
Document Type
Article (peer-reviewed)
Publication Date
2014
Abstract
Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2 h pre/2 h post (-2 h/+2 h) or 24 h pre (-24 h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC 50: 1-20 ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2 h/+2 h, p < 0.0001). PC-515 protected better than Divine 9 in the -24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the -2 h/+2 h regimen (p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.
Recommended Citation
Rodriguez, Aixa, Kyle Kleinbeck, Olga Mizenina, Larisa Kizima, Keith Levendosky, Ninochka Jean-Pierre, Guillermo Villegas, Brian E. Ford, Michael Cooney, Natalia Teleshova, Melissa Robbiani, Betsy C. Herold, Thomas Zydowsky, and José Fernández-Romero. 2014. "In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition," Antiviral Research 108: 88–93.
DOI
10.1016/j.antiviral.2014.05.018
Language
English